Scarica l'app Stockscreener
190.71
0.83%
-1.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$192.30
Aprire:
$193.2
Volume 24 ore:
1.10M
Relative Volume:
1.06
Capitalizzazione di mercato:
$21.22B
Reddito:
$10.52B
Utile/perdita netta:
$999.00M
Rapporto P/E:
22.80
EPS:
8.3628
Flusso di cassa netto:
$1.22B
1 W Prestazione:
+1.97%
1M Prestazione:
+5.68%
6M Prestazione:
+10.24%
1 anno Prestazione:
+17.26%
Intervallo 1D:
$189.94
$193.60
Intervallo di 1 settimana:
$182.36
$193.60
Portata 52W:
$157.20
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
190.71 | 21.39B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest (DGX) Q4 Earnings: What To Expect - Finviz
Market Review: What are Quest Diagnostics Incorporated’s earnings expectationsJuly 2025 Recap & Safe Entry Point Alerts - baoquankhu1.vn
Insurance says I owe nothing, so why is Quest Diagnostics demanding $563? - InkFreeNews.com
Quest Diagnostics Inc (NYSE:DGX) Offers a Reliable Dividend with Strong Growth and Profitability - Chartmill
Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings - Yahoo Finance
Is Quest Diagnostics (DGX) Still Attractive After Recent Share Price Strength? - Yahoo Finance
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Quest Diagnostics Incorporated $DGX Shares Purchased by Peterson Wealth Services - MarketBeat
Principal Financial Group Inc. Sells 27,101 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (DGX) Stock Analysis: Navigating Growth with a 6.57% Upside Potential - DirectorsTalk Interviews
Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease - Chartmill
Barclays Upgrades Quest Diagnostics to Overweight From Equalweight, Adjusts PT to $210 From $195 - marketscreener.com
AlphaQuest LLC Acquires 6,284 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Truist Financial Corp Decreases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Strs Ohio Has $508,000 Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Alpha Cubed Investments LLC Grows Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest 401(k) Win Suit Faces Scrutiny at Third Circuit - USA Herald
3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit - Law360
Is Quest Diagnostics Incorporated in a bullish channelSell Signal & Reliable Intraday Trade Alerts - Mfd.ru
J. Safra Sarasin Holding AG Increases Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Cambiar Investors LLC Lowers Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands - Seeking Alpha
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Weakness - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Cut to Hold at Wall Street Zen - MarketBeat
3rd Circ. Preview: Citizens Bank, Quest Fight Appeals In Jan. - Law360
Stock Market Recap: Can DCWS weather a recessionPortfolio Value Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Rakuten Investment Management Inc. Takes $4.71 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Boston Common Asset Management LLC Has $17.92 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Named to Fortune's Most Admired Companies List for 12th Year - Intellectia AI
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year - Chartmill
QRG Capital Management Inc. Sells 67,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Campbell & CO Investment Adviser LLC Takes $1.01 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Market Moves: Does Apogee Enterprises Inc have consistent dividend growthWeekly Market Report & Community Driven Trade Alerts - baoquankhu1.vn
Short Interest in Quest Diagnostics Incorporated (NYSE:DGX) Increases By 38.4% - MarketBeat
Klein Pavlis & Peasley Financial Inc. Purchases Shares of 5,757 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) Raised to Buy at Wall Street Zen - MarketBeat
How Do Investors Really Feel About Quest Diagnostics Inc? - Benzinga
TKG Advisors LLC Raises Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Nordea Investment Management AB Trims Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Aug PreEarnings: Is Quest Diagnostics Incorporated stock a value trapWatch List & AI Optimized Trade Strategies - baoquankhu1.vn
Quest Diagnostics Inc. (NYSE:DGX): A Prime Pick for Steady, Growing Dividends - Chartmill
Manning & Napier Advisors LLC Sells 11,341 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Market Rankings: What are Quest Diagnostics Incorporateds earnings expectationsJuly 2025 Market Mood & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Baird Adjusts Quest Diagnostics Price Target to $203 From $198, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated $DGX Shares Purchased by Nisa Investment Advisors LLC - MarketBeat
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options - GlobeNewswire Inc.
SG Americas Securities LLC Sells 19,597 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Quest Diagnostics About To Put More Money In Your Pocket (DGX) - Nasdaq
How cyclical is Quest Diagnostics Incorporated (QDI) stock compared to rivalsGDP Growth & Free Safe Capital Growth Stock Tips - Улправда
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):